Also found in: Medical.
VEGFRVascular Endothelial Growth Factor Receptor
References in periodicals archive ?
Session: Poster Session A - Angiogenesis and Antiangiogenesis Agents Date & Time: Friday 6 November 2015, 12:15 PM - 3:15 PM 2nd Presentation Title: Synergistic effect of c-Met inhibitor Savolitinib in combination with a VEGFR inhibitor Fruquintinib in clear cell renal cell carcinoma xenograft models Authors: Yongxin Ren, et al.
The hepatocyte growth factor (HGF) receptor c-Met activation emerges as one of the mechanisms for resistance to anti-VEGF/VEGFR therapies in ccRCC, implying that a combinational inhibition of c-Met and VEGFR pathways may induce a synergistic anti-tumour effect and could produce additional clinical benefit.
In particular, the agent simultaneously inhibits VEGFR, FGFR and also RET which are especially involved in tumor angiogenesis and proliferation of thyroid cancer.
The prognosis of metastatic breast cancer is worse in patients who overexpress HER2 and VEGFR [3], at least without targeted therapy.
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.
It is currently unknown whether the antitumor effect of Ardipusilloside I is caused by binding VEGFR, reduced cell growth and increased apoptosis.
The Telatinib, is a VEGFR inhibitor ready for Phase III development for gastric cancer.
In addition, we developed a similar real-time RT-PCR approach to quantify the expression of VEGFRs, VEGFR-1 and VEGFR-2, in the same tissue pairs.
One key differentiator of BNC420 is that it displays significant selectivity to VEGFR3 over related VEGFR receptors, while other competitive inhibitors of the VEGFR receptors (e.
This potentially makes lenvatinib a first-in-class treatment, especially given that it simultaneously inhibits the kinase activities of FGFR as well as VEGFR.
The lead asset,Telatinib, is a VEGFR inhibitor ready for Phase III development for gastric cancer.
XV-615 has the potential to improve efficacy for treatment of wet AMD because it targets two synergistic pathways mediated by VEGFR and PDGFR.